FAM-CRU conducted the initial Phase IIa study with VPM1002 on healthy newborn infants and is one of the four sites participating in the current Phase IIb expanded study that includes HIV-exposed infants. This site was established in 2003 and has experience conducting studies in a setting with high prevalence for TB and HIV. With this long-standing collaboration, the study team is well trained and highly experienced for TB vaccine research.